ARCHIVE
Archive
Earlier materials, moved here from the home page: a past case, the company finder and worked notes. They are not promise records and make no forecast. For current records, see the home page.
Historical examples — selected past announcements, not current tracking
Company finder: 56 company names, as of 2026-10-12. The 6 with a published record, as of 2026-10-12, are listed first; the others have no reviewed record yet. Listing a company does not mean its current clinical timing has been checked.
ALNY / SELECTED HISTORICAL MILESTONE
3 sources as of 2026-09-26Alnylam Pharmaceuticals
HELIOS-B Phase 3 topline results
EARLIER STATEMENT
Early 2024
Original announcement ↗REVISED GUIDANCE
Late June or early July 2024
Original announcement ↗LATER DISCLOSURE
Outcome announced
Original announcement ↗One question to keep: How did the revised analysis plan differ from the earlier plan, and what did the full results establish?
Historical example. The linked registry is the same study; its dates are different facts from the company’s announcement timing.
More historical examples are kept in the /guidance archive.
Which earlier and later Alnylam statements can I compare?
The HELIOS-B example above, with its original announcements and source-link checks. It is separate from newly observed registry changes and does not trigger alerts.
- Alnylam Pharmaceuticals (ALNY) · Earlier statement: → Later statement: Source-link check: this original issuer URL opened the press-release list in Chrome on . The original recorded URL is retained.
SEC filing copy of this announcement ↗ · Parent 8-K ↗Source-link check: this original issuer URL opened the press-release list in Chrome on . The original recorded URL is retained.
SEC filing copy of this announcement ↗ · Parent 8-K ↗
Notes
Worked notes on single announcements. They are not promise records and make no forecast.
- Lilly eloraTZP at EASD: what would the Phase 2 result actually establish?
- Viking VK2735 maintenance: what did the September readout measure?
- Enhertu’s EU CHMP opinion: what changed, and what has not?
- Ionis FUSION in FUS-ALS: a positive topline result, with detail still to come
- Roche and Ionis sefaxersen: the interim kidney endpoint and the long-term test